Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Study PRECISE-HL: Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation in Advanced Hodgkin Lymphoma

NCT06745076 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT06745076
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06745076 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Study PRECISE-HL: Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation in Advanced Hodgkin Lymphoma
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Recruiting
Start date
March 6, 2025
Completion date
January 3, 2033
Enrollment
125 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hodgkin lymphoma, classic hodgkin lymphoma, lugano classification stage iii hodgkin lymphoma ajcc v8, lugano classification stage iv hodgkin lymphoma ajcc v8